More than 31 million Americans are living with eczema/ atopic dermatitis (AD), a chronic inflammatory skin condition that extends far beyond visible symptoms to disrupt sleep, mental health, and daily ...

J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...

Collaborating institutions in Taiwan report higher risks of atopic disease among children conceived via assisted reproductive ...

Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...

Poplar Therapeutics Launches With $50M Series A to Advance a New Class of Anti-IgE Therapy for Multiple Atopic Conditions ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled ...

Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the ...

Experts break down the most important facts about atopic dermatitis on the hands, including risk factors, treatments, and tips for soothing relief. Atopic dermatitis (AD), the most common form of ...

Children conceived through assisted reproductive technology (ART) were modestly more likely to develop asthma, allergic ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.